CHINA PHARMA HOLDINGS, INC. (CPHI) Return on equity 2016–2025
CHINA PHARMA HOLDINGS, INC. (CPHI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-14.0%FY2025 · since FY2016: -15.6% → -14.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -14.0% | +47.1 pp |
| FY2024 | -61.1% | -19.8 pp |
| FY2023 | -41.3% | +51.3 pp |
| FY2022 | -92.6% | -36.1 pp |
| FY2021 | -56.5% | -20.7 pp |
| FY2020 | -35.8% | +188.3 pp |
| FY2019 | -224.1% | -188.5 pp |
| FY2018 | -35.6% | +9.2 pp |
| FY2017 | -44.8% | -29.2 pp |
| FY2016 | -15.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CPHI financial trends
CPHI RevenueCPHI Net incomeCPHI Net marginCPHI Gross profitCPHI Gross marginCPHI Operating incomeCPHI Operating marginCPHI Operating cash flowCPHI Free cash flowCPHI Capital expendituresCPHI Stock buybacksCPHI Dividends paidCPHI Total assetsCPHI Total liabilitiesCPHI Shareholders’ equityCPHI overview →